If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

Higher drug exposure in women due to lower renal and hepatic clearance and body composition can increase efficacy but also toxicity, highlighting the need to reassess dosing.

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...

When the performance of AI models was assessed within stratified patient subgroups, such as only high-grade breast cancers or only MSI-positive tumors, accuracy fell substantially, revealing that the ...

According to a new study published in the journal Pharmaceuticals, numerous compounds derived from cannabis may help disrupt multiple biological pathways involved in the progression of skin cancer.

In a recently published review, a research team led by MedUni Vienna has highlighted a promising new approach to drug ...

Announcing a new publication for Acta Materia Medica journal. Inflammation is a complex biological response essential for tissue repair in acute settings, yet chronic dysregulation contributes to ...

In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma ...

A single receptor in blood vessels can trigger either harmful inflammation or protective healing, but scientists have ...